Relief Therapeutics Holding AG (RLFTF)

[alexander77]

"Although the FDA phase 2/3 clinical trials remain blinded, some patients have been treated under open label Emergency Use IND on a named-patient basis. Rapid clearing of pneumonitis has been documented on radiography (Figure 1) with concurrent improvement in oxygenation and patient transition from intensive care with mechanical ventilation to home discharge on room air within days of IV infusion."
https://www.authorea.com/users/321659/articles/472151-vasoactive-intestinal-peptide-treats-respiratory-failure-in-covid-19-by-rescuing-the-alveolar-type-ii-cell